Oxford Biomedica Solutions
Divya Tsiros, Ph.D., currently serves as CMC Program Lead at Oxford Biomedica, following a progression from Scientist I to Scientist II within the same organization since March 2022. Prior experience includes a role as Scientist I at Homology Medicines, Inc. from November 2020 to March 2022. Divya's academic background encompasses a Doctor of Philosophy in Biomedical Engineering and Biotechnology, obtained from the University of Massachusetts Lowell, where research involved exploring angiogenic signaling and drug interference in Dr. Matthew Nugent's Lab. Additional teaching experience includes serving as a teaching assistant across various biological disciplines and mentoring undergraduate students in laboratory techniques. Early career experiences include a pre-clinical internship at Celldex Therapeutics and an internship at Expeditors, along with a role as a waitress, demonstrating diverse professional skills.
This person is not in the org chart
This person is not in any teams
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.